UCN2 (urocortin 2) encodes a neuropeptide hormone that functions as a selective ligand for corticotropin-releasing hormone receptor 2 (CRHR2) and plays crucial roles in metabolic regulation and cardiovascular homeostasis 12. The primary function involves suppressing food intake and regulating energy balance, with modified UCN2 peptides demonstrating insulin-sensitizing effects in skeletal muscle through enhanced glucose transport and improved insulin signaling via increased Akt phosphorylation 2. UCN2 treatment increases skeletal muscle mass by modulating both anabolic and catabolic pathways, including upregulation of IGF1 and downregulation of TRIM63, while enhancing protein synthesis rates 1. In cardiovascular contexts, UCN2 exhibits cardioprotective properties, with higher blood levels associated with lower blood pressure and improved lipid profiles in healthy individuals 34. The peptide also demonstrates anti-tumor properties in colorectal cancer by regulating the miR-7/YY1/Fas signaling pathway, enhancing cancer cell sensitivity to apoptosis 5. Clinically, blood UCN2 levels show potential as biomarkers for heart failure assessment, exhibiting negative correlation with cardiac ejection fraction 4, while transcript levels in blood cells may serve as biomarkers for dietary fat consumption patterns in children 6.